BlackRock
QNCX icon

BlackRock’s Quince Therapeutics QNCX Stock Holding History

BlackRock’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31K Sell
1,702
-664
-28% -$15.3K ﹤0.01% 5283
2026
Q1 		$48K Buy
2,366
+6
+0.3% +$1.2K ﹤0.01% 5142
2025
Q4 		$1.58M Buy
2,360
+633
+37% +$319K ﹤0.01% 4185
2025
Q3 		$563K Buy
1,727
+48
+3% +$16K ﹤0.01% 4429
2025
Q2 		$554K Sell
1,679
-48
-3% -$11K ﹤0.01% 4415
2025
Q1 		$459K Sell
1,727
-512
-23% -$156K ﹤0.01% 4423
2024
Q4 		$837K Buy
2,239
+447
+25% +$134K ﹤0.01% 4264
2024
Q3 		$278K Buy
1,792
+18
+1% +$2.58K ﹤0.01% 4460
2024
Q2 		$266K Buy
1,774
+114
+7% +$20.6K ﹤0.01% 4490
2024
Q1 		$352K Sell
1,660
-18
-1% -$4.47K ﹤0.01% 4468
2023
Q4 		$352K Sell
1,678
-4
-0.2% -$801 ﹤0.01% 4511
2023
Q3 		$377K Sell
1,682
-17
-1% -$4.44K ﹤0.01% 4500
2023
Q2 		$511K Buy
1,699
+79
+5% +$24.6K ﹤0.01% 4477
2023
Q1 		$505K Sell
1,620
-131
-7% -$25.6K ﹤0.01% 4525
2022
Q4 		$223K Sell
1,751
-898
-34% -$150K ﹤0.01% 4823
2022
Q3 		$705K Buy
2,649
+150
+6% +$57.1K ﹤0.01% 4615
2022
Q2 		$1.11M Sell
2,499
-4,521
-64% -$3.2M ﹤0.01% 4499
2022
Q1 		$8.69M Buy
7,020
+35
+0.5% +$47.6K ﹤0.01% 3650
2021
Q4 		$17.6M Buy
6,985
+360
+5% +$2.2M ﹤0.01% 3351
2021
Q3 		$121M Buy
6,625
+202
+3% +$3.21M ﹤0.01% 2089
2021
Q2 		$68.1M Sell
6,423
-390
-6% -$3.27M ﹤0.01% 2491
2021
Q1 		$49.1M Buy
6,813
+2
+0% +$14.4K ﹤0.01% 2622
2020
Q4 		$37.8M Buy
6,811
+2,004
+42% +$17.8M ﹤0.01% 2646
2020
Q3 		$48.1M Buy
4,807
+280
+6% +$2.55M ﹤0.01% 2331
2020
Q2 		$41.9M Buy
4,527
+1,263
+39% +$11.6M ﹤0.01% 2364
2020
Q1 		$29.8M Buy
3,264
+336
+11% +$3.32M ﹤0.01% 2386
2019
Q4 		$32.9M Buy
2,928
+2,151
+277% +$13M ﹤0.01% 2606
2019
Q3 		$3.87M Buy
777
+80
+11% +$492K ﹤0.01% 3554
2019
Q2 		$5.93M Buy
+697
New +$4.16M ﹤0.01% 3481

Other funds holding QNCX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return
OA
Operose Advisors Milwaukee, Wisconsin $517M AUM 24.68% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

BlackRock's QNCX Position: Q2 2026 in Review

BlackRock reduced its Quince Therapeutics (QNCX) stake by 28% in Q2 2026, selling an estimated $15.3K and leaving 1,702 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #5283.

BlackRock first reported a position in QNCX in Q2 2019 and has held it in 29 quarters since. The position peaked at $121M in Q3 2021. 16 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • BlackRock held 1,702 shares of Quince Therapeutics worth $31K as of Q2 2026.
  • BlackRock sold 664 Quince Therapeutics shares in Q2 2026, an estimated $15.3K.
  • Quince Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5283 holding.
  • BlackRock first reported a position in Quince Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • BlackRock's Quince Therapeutics position peaked at $121M in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.